Chimeric alphavirus vaccine candidates protect mice from intranasal challenge with western equine encephalitis virus

Svetlana Atasheva, Eryu Wang, A. Paige Adams, Kenneth S. Plante, Sai Ni, Katherine Taylor, Mary E. Miller, Ilya Frolov, Scott Weaver

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

We developed two types of chimeric Sindbis virus (SINV)/western equine encephalitis virus (WEEV) alphaviruses to investigate their potential use as live virus vaccines against WEE. The first-generation vaccine candidate, SIN/CO92, was derived from structural protein genes of WEEV strain CO92-1356, and two second-generation candidates were derived from WEEV strain McMillan. For both first- and second-generation vaccine candidates, the nonstructural protein genes were derived from SINV strain AR339. Second-generation vaccine candidates SIN/SIN/McM and SIN/EEE/McM included the envelope glycoprotein genes from WEEV strain McMillan; however, the amino-terminal half of the capsid, which encodes the RNA-binding domain, was derived from either SINV or eastern equine encephalitis virus (EEEV) strain FL93-939. All chimeric viruses replicated efficiently in mammalian and mosquito cell cultures and were highly attenuated in 6-week-old mice. Vaccinated mice developed little or no detectable disease and showed little or no evidence of challenge virus replication; however, all developed high titers of neutralizing antibodies. Upon intranasal challenge with high doses of virulent WEEV strains, mice vaccinated with ≥105 PFU of SIN/CO92 or ≥104 PFU of SIN/SIN/McM or SIN/EEE/McM were completely protected from disease. These findings support the potential use of these live-attenuated vaccine candidates as safe and effective vaccines against WEE.

Original languageEnglish (US)
Pages (from-to)4309-4319
Number of pages11
JournalVaccine
Volume27
Issue number32
DOIs
StatePublished - Jul 9 2009

Fingerprint

Western Equine Encephalitis Viruses
Western equine encephalitis virus
Alphavirus
Sindbis Virus
Vaccines
Sindbis virus
vaccines
mice
live vaccines
Eastern equine encephalitis virus
Viruses
Attenuated Vaccines
Capsid
Cerebral Palsy
viruses
Virus Replication
Neutralizing Antibodies
Culicidae
capsid
genes

Keywords

  • Alphavirus
  • Vaccine
  • Virulence
  • Western equine encephalitis virus

ASJC Scopus subject areas

  • Immunology and Microbiology(all)
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)
  • Molecular Medicine

Cite this

Chimeric alphavirus vaccine candidates protect mice from intranasal challenge with western equine encephalitis virus. / Atasheva, Svetlana; Wang, Eryu; Adams, A. Paige; Plante, Kenneth S.; Ni, Sai; Taylor, Katherine; Miller, Mary E.; Frolov, Ilya; Weaver, Scott.

In: Vaccine, Vol. 27, No. 32, 09.07.2009, p. 4309-4319.

Research output: Contribution to journalArticle

Atasheva, S, Wang, E, Adams, AP, Plante, KS, Ni, S, Taylor, K, Miller, ME, Frolov, I & Weaver, S 2009, 'Chimeric alphavirus vaccine candidates protect mice from intranasal challenge with western equine encephalitis virus', Vaccine, vol. 27, no. 32, pp. 4309-4319. https://doi.org/10.1016/j.vaccine.2009.05.011
Atasheva, Svetlana ; Wang, Eryu ; Adams, A. Paige ; Plante, Kenneth S. ; Ni, Sai ; Taylor, Katherine ; Miller, Mary E. ; Frolov, Ilya ; Weaver, Scott. / Chimeric alphavirus vaccine candidates protect mice from intranasal challenge with western equine encephalitis virus. In: Vaccine. 2009 ; Vol. 27, No. 32. pp. 4309-4319.
@article{c5306f89308f4a6bbea6d1891945cdb7,
title = "Chimeric alphavirus vaccine candidates protect mice from intranasal challenge with western equine encephalitis virus",
abstract = "We developed two types of chimeric Sindbis virus (SINV)/western equine encephalitis virus (WEEV) alphaviruses to investigate their potential use as live virus vaccines against WEE. The first-generation vaccine candidate, SIN/CO92, was derived from structural protein genes of WEEV strain CO92-1356, and two second-generation candidates were derived from WEEV strain McMillan. For both first- and second-generation vaccine candidates, the nonstructural protein genes were derived from SINV strain AR339. Second-generation vaccine candidates SIN/SIN/McM and SIN/EEE/McM included the envelope glycoprotein genes from WEEV strain McMillan; however, the amino-terminal half of the capsid, which encodes the RNA-binding domain, was derived from either SINV or eastern equine encephalitis virus (EEEV) strain FL93-939. All chimeric viruses replicated efficiently in mammalian and mosquito cell cultures and were highly attenuated in 6-week-old mice. Vaccinated mice developed little or no detectable disease and showed little or no evidence of challenge virus replication; however, all developed high titers of neutralizing antibodies. Upon intranasal challenge with high doses of virulent WEEV strains, mice vaccinated with ≥105 PFU of SIN/CO92 or ≥104 PFU of SIN/SIN/McM or SIN/EEE/McM were completely protected from disease. These findings support the potential use of these live-attenuated vaccine candidates as safe and effective vaccines against WEE.",
keywords = "Alphavirus, Vaccine, Virulence, Western equine encephalitis virus",
author = "Svetlana Atasheva and Eryu Wang and Adams, {A. Paige} and Plante, {Kenneth S.} and Sai Ni and Katherine Taylor and Miller, {Mary E.} and Ilya Frolov and Scott Weaver",
year = "2009",
month = "7",
day = "9",
doi = "10.1016/j.vaccine.2009.05.011",
language = "English (US)",
volume = "27",
pages = "4309--4319",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "32",

}

TY - JOUR

T1 - Chimeric alphavirus vaccine candidates protect mice from intranasal challenge with western equine encephalitis virus

AU - Atasheva, Svetlana

AU - Wang, Eryu

AU - Adams, A. Paige

AU - Plante, Kenneth S.

AU - Ni, Sai

AU - Taylor, Katherine

AU - Miller, Mary E.

AU - Frolov, Ilya

AU - Weaver, Scott

PY - 2009/7/9

Y1 - 2009/7/9

N2 - We developed two types of chimeric Sindbis virus (SINV)/western equine encephalitis virus (WEEV) alphaviruses to investigate their potential use as live virus vaccines against WEE. The first-generation vaccine candidate, SIN/CO92, was derived from structural protein genes of WEEV strain CO92-1356, and two second-generation candidates were derived from WEEV strain McMillan. For both first- and second-generation vaccine candidates, the nonstructural protein genes were derived from SINV strain AR339. Second-generation vaccine candidates SIN/SIN/McM and SIN/EEE/McM included the envelope glycoprotein genes from WEEV strain McMillan; however, the amino-terminal half of the capsid, which encodes the RNA-binding domain, was derived from either SINV or eastern equine encephalitis virus (EEEV) strain FL93-939. All chimeric viruses replicated efficiently in mammalian and mosquito cell cultures and were highly attenuated in 6-week-old mice. Vaccinated mice developed little or no detectable disease and showed little or no evidence of challenge virus replication; however, all developed high titers of neutralizing antibodies. Upon intranasal challenge with high doses of virulent WEEV strains, mice vaccinated with ≥105 PFU of SIN/CO92 or ≥104 PFU of SIN/SIN/McM or SIN/EEE/McM were completely protected from disease. These findings support the potential use of these live-attenuated vaccine candidates as safe and effective vaccines against WEE.

AB - We developed two types of chimeric Sindbis virus (SINV)/western equine encephalitis virus (WEEV) alphaviruses to investigate their potential use as live virus vaccines against WEE. The first-generation vaccine candidate, SIN/CO92, was derived from structural protein genes of WEEV strain CO92-1356, and two second-generation candidates were derived from WEEV strain McMillan. For both first- and second-generation vaccine candidates, the nonstructural protein genes were derived from SINV strain AR339. Second-generation vaccine candidates SIN/SIN/McM and SIN/EEE/McM included the envelope glycoprotein genes from WEEV strain McMillan; however, the amino-terminal half of the capsid, which encodes the RNA-binding domain, was derived from either SINV or eastern equine encephalitis virus (EEEV) strain FL93-939. All chimeric viruses replicated efficiently in mammalian and mosquito cell cultures and were highly attenuated in 6-week-old mice. Vaccinated mice developed little or no detectable disease and showed little or no evidence of challenge virus replication; however, all developed high titers of neutralizing antibodies. Upon intranasal challenge with high doses of virulent WEEV strains, mice vaccinated with ≥105 PFU of SIN/CO92 or ≥104 PFU of SIN/SIN/McM or SIN/EEE/McM were completely protected from disease. These findings support the potential use of these live-attenuated vaccine candidates as safe and effective vaccines against WEE.

KW - Alphavirus

KW - Vaccine

KW - Virulence

KW - Western equine encephalitis virus

UR - http://www.scopus.com/inward/record.url?scp=67649472422&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67649472422&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2009.05.011

DO - 10.1016/j.vaccine.2009.05.011

M3 - Article

VL - 27

SP - 4309

EP - 4319

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 32

ER -